Vaccinex, Inc. (VCNX): Price and Financial Metrics
Vaccinex, Inc. (VCNX)
Today's Latest Price: $2.12 USD
Updated Dec 4 4:00pm
Add VCNX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
VCNX Stock Summary
- VCNX's price/sales ratio is 74.5; that's higher than the P/S ratio of 96.45% of US stocks.
- With a year-over-year growth in debt of 695.77%, Vaccinex Inc's debt growth rate surpasses 97.27% of about US stocks.
- Vaccinex Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -79.19%, greater than the shareholder yield of only 4.45% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Vaccinex Inc are ERYP, NVEC, CBIO, VNE, and PULM.
- VCNX's SEC filings can be seen here. And to visit Vaccinex Inc's official web site, go to www.vaccinex.com.
VCNX Stock Price Chart Interactive Chart >
VCNX Price/Volume Stats
| Current price | $2.12 | 52-week high | $12.23 |
| Prev. close | $2.09 | 52-week low | $1.63 |
| Day low | $2.07 | Volume | 184,000 |
| Day high | $2.14 | Avg. volume | 493,708 |
| 50-day MA | $1.93 | Dividend yield | N/A |
| 200-day MA | $3.92 | Market Cap | 47.46M |
Vaccinex, Inc. (VCNX) Company Bio
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.
Loading social stream, please wait...